JP2025502266A - 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法 - Google Patents

有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法 Download PDF

Info

Publication number
JP2025502266A
JP2025502266A JP2024541996A JP2024541996A JP2025502266A JP 2025502266 A JP2025502266 A JP 2025502266A JP 2024541996 A JP2024541996 A JP 2024541996A JP 2024541996 A JP2024541996 A JP 2024541996A JP 2025502266 A JP2025502266 A JP 2025502266A
Authority
JP
Japan
Prior art keywords
upadacitinib
patient
daily dose
patients
rinvoq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502266A5 (https=
Inventor
モハメッド，モハメッド－エスラーム・エフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2025502266A publication Critical patent/JP2025502266A/ja
Publication of JP2025502266A5 publication Critical patent/JP2025502266A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024541996A 2022-01-13 2023-01-13 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法 Pending JP2025502266A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263299324P 2022-01-13 2022-01-13
US63/299,324 2022-01-13
US202263320149P 2022-03-15 2022-03-15
US63/320,149 2022-03-15
PCT/US2023/060648 WO2023137440A2 (en) 2022-01-13 2023-01-13 Method of administering upadacitinib to avoid adverse drug interactions and effects

Publications (2)

Publication Number Publication Date
JP2025502266A true JP2025502266A (ja) 2025-01-24
JP2025502266A5 JP2025502266A5 (https=) 2026-01-22

Family

ID=87279802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541996A Pending JP2025502266A (ja) 2022-01-13 2023-01-13 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法

Country Status (8)

Country Link
US (1) US20230233555A1 (https=)
EP (1) EP4463161A4 (https=)
JP (1) JP2025502266A (https=)
KR (1) KR20240148324A (https=)
AU (1) AU2023206381A1 (https=)
CA (1) CA3246767A1 (https=)
MX (1) MX2024008557A (https=)
WO (1) WO2023137440A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570664B2 (en) 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11564922B2 (en) * 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment

Also Published As

Publication number Publication date
WO2023137440A3 (en) 2023-10-05
AU2023206381A1 (en) 2024-07-25
EP4463161A2 (en) 2024-11-20
EP4463161A4 (en) 2026-01-14
MX2024008557A (es) 2024-09-11
CA3246767A1 (en) 2023-07-20
US20230233555A1 (en) 2023-07-27
KR20240148324A (ko) 2024-10-11
WO2023137440A2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP2025502266A (ja) 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法
JP2026001038A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
KR101524165B1 (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
US8957071B2 (en) Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20250262193A1 (en) Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia Gravis
TWI879737B (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
JP2023522623A (ja) 全身性過炎症反応を伴う状態の処置に使用するエクリタセルチブ
Chen et al. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection
AM et al. Full prescribing information
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
JP2025516634A (ja) ミエリンオリゴデンドロサイト糖タンパク質抗体疾患（ｍｏｇａｄ）の治療における使用のためのブルトンチロシンキナーゼ阻害剤
JP6042886B2 (ja) 早漏症治療用の薬学組成物
JP2024520150A (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
CN118891046A (zh) 施用乌帕替尼以避免不良药物相互作用和反应的方法
AB Summary of product characteristics
US12409172B2 (en) Dosage regimen
US20260060974A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
KR20250084183A (ko) 다발성 경화증에 대한 치료용 티로신 키나제 저해제
Venkitakrishnan et al. Drug Corner Baricitinib: Delineating a New Treatment Option in COVID-19
TW202545529A (zh) 組合療法
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260113